|
|
|
| Dec. 14, 2005 |
Amgen to Acquire Abgenix for $22.50 Per Share; Provides Amgen With Full Ownership of Panitumumab and Eliminates a Denosumab Royalty
|
| Dec. 12, 2005 |
New Phase 3 Data Show Potential Benefits of Aranesp(R) Dosed Every Three Weeks for Chemotherapy-Induced Anemia; Aranesp Treatment Achieved and Maintained Target Hemoglobin Levels and Reduced Incidence of Red Blood Cell Transfusions
|
| Dec. 12, 2005 |
Interim Long-Term Follow-up Data Show AMG 531 Increases Platelets in Patients with Immune Thrombocytopenic Purpura; Results Suggest Once-Weekly Dosing of AMG 531 Results in Sustained Platelet Response
|
| Dec. 11, 2005 |
Updated Interim Aranesp(R) Phase 2 Data Suggest Major Response in Anemic Patients with Myelodysplastic Syndrome (MDS); Patients with Bone Marrow Disorder Also Showed Improvements in Hemoglobin Levels and Fatigue
|
| Dec. 8, 2005 |
The Wellness Community and Amgen Partner with Professional Cyclist George Hincapie to Launch 'Breakaway from Cancer' Initiative
|
| Nov. 15, 2005 |
Amgen Foundation Donates $500,000 to South Asia Earthquake Relief Efforts
|
| Nov. 13, 2005 |
Two-Year Trial Results of Amgen Investigational Therapy for Bone Loss, Denosumab, Show Increased Bone Mineral Density with Twice-Yearly Dosing
|
| Nov. 13, 2005 |
Treatment Has Demonstrated Improvement in Physical Function and Kept Joint Damage from Progressing at Three Years
|
| Nov. 12, 2005 |
Data Show Aranesp(R) (Darbepoetin Alfa) Administered Once Monthly Maintains Hemoglobin Levels in Chronic Kidney Disease Patients with Anemia
|
| Nov. 10, 2005 |
Nominations Open for the Amgen Award for Science Teaching Excellence; 19 Outstanding Teachers Will Be Recognized in Communities Where Amgen Operates
|
| Nov. 9, 2005 |
Amgen Files Lawsuit Against Roche for Patent Infringement
|
| Nov. 3, 2005 |
Panitumumab Significantly Improves Progression-Free Survival in Phase 3 Randomized Metastatic Colorectal Cancer Study
|
| Nov. 3, 2005 |
Media Notification/Webcast Notification - Amgen and Abgenix to Conduct Conference Call and Webcast Regarding Panitumumab Pivotal Study Results - November 3, 2005, 8:00 am PT
|
| Nov. 2, 2005 |
Amgen Announces Sponsorship of World-Class Cycling Event; Company to Join with the Wellness Community to Raise Awareness and Funds to Help People Fight Cancer
|
| Oct. 28, 2005 |
European Commission Approves Kepivance(TM) (Palifermin) for Oral Mucositis in Cancer Patients Undergoing Blood and Bone Marrow Transplant
|
| Oct. 19, 2005 |
Amgen's Third Quarter 2005 Adjusted Earnings Per Share Increased 33 Percent to 85 Cents; Third Quarter 2005 GAAP Earnings Per Share Increased to 77 Cents from 18 Cents
|
| Sep. 15, 2005 |
FDA Expands Neulasta(R) Label; New Label Extends First-Cycle Protection From Infection To Cancer Patients Receiving Moderately Myelosuppressive Chemotherapy
|
| Sep. 6, 2005 |
Amgen Announces FDA Licensure of Two New Manufacturing Facilities; Company Continues to Meet Increased Demand for Its Novel Therapeutics
|
| Sep. 2, 2005 |
Amgen Names Phyllis Piano Vice President, Corporate Communications and Philanthropy
|
| Sep. 2, 2005 |
Amgen Announces Initiation of Phase 3 Trial to Evaluate the Impact of Treating Anemia with Darbepoetin Alfa in Patients with Heart Failure to Reduce Mortality and Hospitalization
|
| Sep. 1, 2005 |
Amgen Donates $2.5 Million to Hurricane Katrina Relief Efforts
|
| Aug. 10, 2005 |
Amgen Names Michael Kelly as Chief Accounting Officer
|
| Aug. 4, 2005 |
Amgen Strengthens Focus on Oncology Pipeline, Names David R. Parkinson to New Role in Research and Development Organization
|
| Aug. 2, 2005 |
Amgen Adopts ``Guiding Principles'' for Direct-to-Consumer Advertising
|
| Aug. 1, 2005 |
Abgenix and Amgen Announce FDA Grants Panitumumab Fast Track Designation for Metastatic Colorectal Cancer
|
| Jul. 28, 2005 |
Kepivance(TM) (palifermin) Receives Positive Regulatory Opinion for Approval in Europe
|
| Jul. 19, 2005 |
Amgen's Second Quarter 2005 Adjusted Earnings Per Share Increased 42 Percent to 88 Cents
|
| Jul. 6, 2005 |
Interim Data Suggest Major Response with Aranesp(R) in Anemic Patients with Myelodysplastic Syndromes (MDS)
|
| Jun. 1, 2005 |
FDA Expands ENBREL Psoriatic Arthritis Indication -- ENBREL Approved as First and Only Treatment to Improve Physical Function in These Patients
|
| May. 19, 2005 |
2005 Recipients of Amgen Award for Science Teaching Excellence Announced; 19 Outstanding Science Teachers and Their Schools Recognized in Communities Across U.S. and Puerto Rico
|
| May. 17, 2005 |
Amgen Names Jim Daly, Senior Vice President, North America Commercial Operations
|
| May. 17, 2005 |
Further Phase 2 Data Confirm Panitumumab Single-Agent Antitumor Activity in Patients with Metastatic Colorectal Cancer
|
| May. 15, 2005 |
Aranesp Dosed Every Three Weeks Achieved and Maintained Target Hemoglobin Levels in Patients with Chemotherapy-Induced Anemia
|
| May. 15, 2005 |
Final Results of Phase 3 Head-to-Head Study Demonstrate Aranesp Dosed Every Two Weeks is Comparable to Epoetin Alfa Dosed Weekly in Cancer Patients with Chemotherapy-Induced Anemia
|
| May. 15, 2005 |
Large Community-Based Clinical Trial in Older Cancer Patients Suggests Benefits of Neulasta in First and Subsequent Cycles Of Chemotherapy
|
| May. 6, 2005 |
Amgen Submits Supplemental Biologics License Application for Aranesp Extended Dosing; Phase 3 Study Evaluated Aranesp Dosed Once Every Three Weeks in Patients with Chemotherapy-Induced Anemia
|
| May. 5, 2005 |
Amgen Announces Expiration and Results of its Exchange Offer for Its Outstanding Liquid Yield Option Notes Due 2032
|
| May. 4, 2005 |
Amgen Announces One-Day Extension of Its Exchange Offer for Its Outstanding Liquid Yield Option Notes Due 2032
|
| May. 3, 2005 |
Amgen Announces Plans to Webcast Selected Management Presentations
|
| Apr. 26, 2005 |
Phase 3 Clinical Trial Initiated to Evaluate the Use of Panitumumab Therapy for First-Line Treatment of Metastatic Colorectal Cancer; Study Evaluates Panitumumab Administered With Bevacizumab and Chemotherapy
|
| Apr. 21, 2005 |
Amgen's First Quarter 2005 Adjusted Earnings Per Share Increased 26 Percent to 72 Cents
|
| Apr. 11, 2005 |
Multimedia Available: Landmark Trial to Link Reduction in Cardiovascular Risk With Treatment of Anemia in Diabetics With Chronic Kidney Disease
|
| Apr. 11, 2005 |
Landmark Trial to Link Reduction in Cardiovascular Risk With Treatment of Anemia in Diabetics With Chronic Kidney Disease
|
| Apr. 6, 2005 |
Amgen Commences Exchange Offer for Its Outstanding Liquid Yield Option Notes Due 2032
|
| Mar. 28, 2005 |
Landmark Trial Will Evaluate the Impact of Treating Anemia on Cardiovascular Outcomes in Patients with Chronic Kidney Disease and Type 2 Diabetes
|
| Mar. 2, 2005 |
Amgen Announces Results of Its Repurchase of Tendered Liquid Yield Option Notes Due 2032
|
| Feb. 25, 2005 |
Phase 3 Study Published in The Journal of Clinical Oncology Shows First-Cycle Administration of Neulasta Significantly Lowers Incidence of Neutropenia with Related Fever and Hospitalization
|
| Feb. 22, 2005 |
Amgen Announces One-Time Cash Payment and Additional Put Right for Liquid Yield Option Notes Due 2032
|
| Feb. 18, 2005 |
Treatment with ENBREL Had a Positive Effect on Activities of Daily Living for Patients with Psoriasis
|
| Feb. 11, 2005 |
Following Complete Review of Phase 2 Trial Data Amgen Confirms Decision to Halt GDNF Study; Comprehensive Review of Scientific Findings, Patient Safety, Drove Decision
|
| Jan. 31, 2005 |
Amgen Announces Put Option Notification for Liquid Yield Option Notes Due 2032
|
| Jan. 27, 2005 |
Amgen's Fourth Quarter 2004 Adjusted Earnings Per Share Increased 26 Percent to 58 Cents; Full Year 2004 Adjusted Earnings Per Share Increased 26 Percent to $2.40
|
| Jan. 21, 2005 |
Amgen Announces Webcast of 2004 Fourth Quarter and Full Year Financial Results
|
| Jan. 11, 2005 |
Amgen Significantly Expands Support of Patient Assistance Programs; Financial Support To Help Ensure Patients Have Access To Innovative Therapies Critical To Care
|
| Jan. 3, 2005 |
Amgen Donates $1 Million and Establishes Tsunami Relief Program; Staff Donations, Company Contributions To Help South Asia Victims
|
|
|
|
|
|
|
|
|
|
|
|
